Ersofermin
Ersofermin is a recombinant human fibroblast growth factor 19 (rhFGF19) analog that is being investigated for its potential therapeutic effects in treating metabolic disorders, particularly non-alcoholic steatohepatitis (NASH). It is designed to mimic the activity of the naturally occurring FGF19, a hormone involved in regulating bile acid synthesis, glucose metabolism, and lipid metabolism.
Mechanism of Action[edit | edit source]
Ersofermin functions by activating the FGF receptor 4 (FGFR4) and its co-receptor β-Klotho, which are primarily expressed in the liver. Upon activation, these receptors initiate a signaling cascade that results in the suppression of bile acid synthesis, improvement in insulin sensitivity, and reduction of liver fat accumulation. This makes Ersofermin a promising candidate for addressing the underlying pathophysiology of NASH, which is characterized by liver inflammation, fat accumulation, and fibrosis.
Clinical Development[edit | edit source]
Ersofermin is currently undergoing clinical trials to evaluate its safety and efficacy in patients with NASH. Early-phase studies have shown that Ersofermin can significantly reduce liver fat content and improve liver function markers. Ongoing trials aim to further assess its impact on liver histology and long-term outcomes in NASH patients.
Potential Benefits[edit | edit source]
The potential benefits of Ersofermin in treating NASH include:
- Reduction in liver fat content
- Improvement in liver enzyme levels
- Decrease in liver inflammation and fibrosis
- Enhancement of insulin sensitivity
Side Effects and Safety[edit | edit source]
As with any investigational drug, the safety profile of Ersofermin is being closely monitored in clinical trials. Commonly reported side effects include gastrointestinal disturbances, such as nausea and diarrhea, as well as potential alterations in lipid profiles. Long-term safety data are still being collected.
Regulatory Status[edit | edit source]
Ersofermin is not yet approved for clinical use and is available only through participation in clinical trials. The results of ongoing studies will determine its future regulatory approval and availability.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
